Introduction
 The management of atrial fibrillation (AF) represents a significant burden on the UK National Health Service (NHS), both in primary and secondary care 1  With the incidence and prevalence of AF predicted to rise significantly in the coming years 2 , this economic burden has the potential to increase unless management efficiencies are made  A clear understanding of the resource use and costs associated with the current management of AF is important in informing future planning and policy development
Methods

Design:
 A retrospective, observational research study undertaken in 8 UK primary care practices, three of which provided their own anticoagulation services (i. 
Study patients and data collection:
 825 adult patients with AF (≥18 years at diagnosis), providing written informed consent for researcher access to their medical records  Patients diagnosed less than 12 weeks before data collection, those with secondary AF and those with no diagnosis date were excluded  For the purposes of this study the first 12 weeks of management following diagnosis of AF was defined as the 'initiation phase'. The period from week 12 onwards was referred to as the 'maintenance phase'  For patients who had been recently diagnosed with AF (<9 months before data collection), data were collected on the initiation phase only  For patients diagnosed more than 3 years before data collection, data were collected on the most recent 3 years of management (i.e. the maintenance phase only)  Patients diagnosed between 9 months and 3 years before data collection provided data on both the initiation and maintenance phases of management
Data analysis:
 Costs (Great British Pounds, GBP) were assigned to AF-related healthcare resource use (medications, primary care visits, secondary care attendances [emergency department, outpatient and daycare], hospitalisations, investigations and blood tests) using published NHS reference costs [3] [4] [5] . These were used to calculate a total cost per patient for the initiation and maintenance phases of management (as applicable). The cost of primary care anticoagulation visits (for centres providing anticoagulation services) was not included in the total costs, as details of anticoagulation visits for patients in other practices (which would have taken place in secondary care) were not available in the primary care records and so were outside the scope of data collection  Analysis included stratification of costs by type of centre (i.e. practices with / without their own anticoagulation service)  Multiple regression analysis was performed to determine which combination of variables contributed most to total costs during both the initiation and maintenance phases of management  Where costs are presented in Euros (€) or US Dollars ($), conversion from Great British Pounds (£) was based on 2010 exchange rates  The between-patient range of costs was high, with the care of most patients (57% in the initiation phase and 72% in the maintenance phase) costing less than £500 (€609/$779) per patient / per patient year. Thirty three percent of patients in the initiation phase and 12% in the maintenance phase had care costs of more than £1,000 (€1,218/$1,559) per patient / per patient year (Figure 2 ).
* 1 SD = Standard deviation * 2 Mean cost for each component in initiation or maintenance phase, divided by the mean total cost for that period * 3 Excluding anticoagulation visits
 Data were collected on a total of 825 patients. Data were available on the initiation phase from 310 patients and from 769 patients on the maintenance phase.  Four hundred and sixty two patients (56%) were male ; the mean age at diagnosis of AF was 70.5 years (range 22.4-95.7 years).
Figure 3: Total costs, stratified by type of centre
 The mean maintenance phase cost per patient year was significantly higher for practices providing anticoagulation services (£555/€676/$865) than for practices without these services (£421/€513/$656), p=0.002 (Figure 3 ), even though primary care visits directly attributable to anticoagulation were excluded from the analysis.  The higher maintenance phase costs in these centres results from significantly higher costs for investigations (p<0.0001), blood testing (p<0.0001), primary care visits (p<0.0001) and secondary care attendances (p=0.008). There was no significant difference between the two types of centre in the maintenance phase costs for AF medications (p=0.337) or inpatient admissions (p=0.141). 2 Added cost per hospitalisation, ECG or daycare attendance in the initiation phase  In the initiation phase, the variables contributing most to total cost were age at diagnosis (reducing costs by £16 for each increasing year of age) and hypertension (adding £457 to total costs) ( Table 2 part a). However, these variables combined, only explained 5% of the variability in initiation phase costs (r=0.05).
 In the maintenance phase, the patient variables contributing most to total cost were the presence of congestive heart disease, structural heart disease and diabetes, which added £152, £161 and £182 (respectively) to the total cost per year in the maintenance phase (Table 2 part b). The presence of dyslipidaemia reduced maintenance phase costs by £94 per year. The number of hospitalisations, ECGs and daycare attendances in the initiation phase were also found to contribute to increased maintenance phase costs. All of these patient and initiation phase variables combined, explained 18% of the variability in maintenance phase costs (r=0.18).
P=0.24 P=0.002
Conclusions:
• This study confirms that inpatient admissions and secondary care attendances contribute most to total AF management costs. Future work should focus on how to safely reduce avoidable hospital admissions.
• The between-patient range in costs was high, with a small number of patients at the high end of the cost distribution. Although we identified a number of significant variables predictive of high care costs, none of those analyzed accounted for much variability in the total cost of AF management. This suggests that it is often not possible to predict which patients will be high NHS resource users
• Maintenance phase costs were significantly higher for patients managed by practices providing anticoagulation services than patients for whom anticoagulation was managed in secondary care, even though the cost of primary care anticoagulation visits was excluded from this analysis. This may be due to the increased patient contact for anticoagulation, generating further healthcare professional activity, but this cannot be determined from the data collected. 
